Newsfeeds - Spark Newswire

3 minute read

Aadi Bioscience Announces $72.5M Private Placement Equity Financing Of 3,373,526 Shares At A Price Of $12.50/Share

September 22, 4:03 PM

LOS ANGELES, Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in

AADI

1 minute read

Earnings

Aadi Bioscience: Q2 Earnings Insights

By Benzinga Insights

August 10, 8:53 AM

Aadi Bioscience (NASDAQ:AADI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

AADI

11 minute read

Earnings Scheduled For August 10, 2022

By Benzinga Insights

August 10, 5:33 AM

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.

AADI

1 minute read

Earnings

Aadi Bioscience: Q1 Earnings Insights

By Benzinga Insights

May 12, 11:02 AM

Aadi Bioscience (NASDAQ:AADI) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Aadi Bioscience beat estimated earnings by 7.04%, reporting an EPS of $-0.66 versus an estimate of $-0.71.

AADI

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

May 11, 12:28 PM

On Wednesday, 807 companies reached new 52-week lows.

AADI

1 minute read

News

Aadi Bioscience Announces Collaborations With Next Generation Sequencing Leaders

By Benzinga Newsdesk

May 9, 8:04 AM

Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial Collaborations

AADI

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

April 28, 3:31 PM

During Thursday, 849 stocks hit new 52-week lows.

AADI

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

April 27, 2:41 PM

Wednesday's session saw 784 companies set new 52-week lows.

AADI

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Aadi Bioscience, Lowers Price Target To $48

By Benzinga Insights

April 11, 1:43 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Aadi Bioscience (NASDAQ:AADI) and lower its price target from $49.00 to $48.00. Shares of Aadi Bioscience are trading down 4.87% over the last 24 hours, at $16.62 per share.

AADI